MX2021011939A - Compuestos neuroactivos y metodos de uso de los mismos. - Google Patents

Compuestos neuroactivos y metodos de uso de los mismos.

Info

Publication number
MX2021011939A
MX2021011939A MX2021011939A MX2021011939A MX2021011939A MX 2021011939 A MX2021011939 A MX 2021011939A MX 2021011939 A MX2021011939 A MX 2021011939A MX 2021011939 A MX2021011939 A MX 2021011939A MX 2021011939 A MX2021011939 A MX 2021011939A
Authority
MX
Mexico
Prior art keywords
methods
neuroactive compounds
sterol
subject
disorder
Prior art date
Application number
MX2021011939A
Other languages
English (en)
Inventor
Michael C Quirk
James J Doherty
Botella Gabriel Martinez
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2021011939A publication Critical patent/MX2021011939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan métodos para tratar un paciente que padece de un trastorno de síntesis de esterol o un trastorno de deficiencia de esterol, por ejemplo, síndrome Smith-Lemli-Opitz, el método comprende administrar al sujeto una cantidad efectiva de un compuesto que modula el receptor NMDA.
MX2021011939A 2014-10-07 2017-04-07 Compuestos neuroactivos y metodos de uso de los mismos. MX2021011939A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462060932P 2014-10-07 2014-10-07

Publications (1)

Publication Number Publication Date
MX2021011939A true MX2021011939A (es) 2021-11-03

Family

ID=55653736

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004684A MX2017004684A (es) 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos.
MX2021011939A MX2021011939A (es) 2014-10-07 2017-04-07 Compuestos neuroactivos y metodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017004684A MX2017004684A (es) 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos.

Country Status (17)

Country Link
US (2) US20170304321A1 (es)
EP (1) EP3204011A4 (es)
JP (3) JP2017530982A (es)
KR (1) KR20170065637A (es)
CN (2) CN112121171A (es)
AU (2) AU2015330906A1 (es)
BR (1) BR112017007053A2 (es)
CA (1) CA2963938C (es)
IL (2) IL292465A (es)
MX (2) MX2017004684A (es)
NZ (1) NZ730862A (es)
PE (1) PE20170907A1 (es)
PH (1) PH12017500639A1 (es)
RU (1) RU2764702C2 (es)
SG (2) SG10202011773UA (es)
WO (1) WO2016057713A1 (es)
ZA (1) ZA201702545B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2753632T (lt) 2011-09-08 2023-07-10 Sage Therapeutics, Inc. Neuroaktyvieji steroidai, jų kompozicijos ir naudojimas
ES2699445T3 (es) 2013-03-13 2019-02-11 Sage Therapeutics Inc Esteroides neuroactivos y métodos de utilización de los mismos
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EA201990684A1 (ru) 2013-12-24 2020-12-30 Вирджиния Коммонвелт Юниверсити Способы применения оксигенированных холестеролсульфатов (ocs)
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA2991311A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
IL256710B2 (en) 2015-07-06 2024-01-01 Sage Therapeutics Inc Oxysterols and methods of using them
MX2020010690A (es) 2015-07-06 2022-02-25 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
PL3436022T3 (pl) 2016-04-01 2022-08-08 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SI3481846T1 (sl) 2016-07-07 2021-11-30 Sage Therapeutics, Inc. 11-substituirani 24-hidroksisteroli za uporabo pri zdravljenju stanj, povezanih z NMDA
MX2019001323A (es) * 2016-08-02 2019-07-04 Univ Virginia Commonwealth Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
CA3234484A1 (en) * 2016-10-18 2018-04-26 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
RU2019115112A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
EP3335730A1 (en) * 2016-12-15 2018-06-20 Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) Compounds for treating x-linked adrenoleukodystrophy
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO2006037016A2 (en) * 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
EP2207542A2 (en) * 2007-11-06 2010-07-21 N.V. Organon A method of hormone suppression in humans
KR20110016891A (ko) * 2008-05-09 2011-02-18 에모리 유니버시티 신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질
WO2010065709A2 (en) * 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
LT2753632T (lt) * 2011-09-08 2023-07-10 Sage Therapeutics, Inc. Neuroaktyvieji steroidai, jų kompozicijos ir naudojimas
EP2841067A4 (en) * 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
US9737522B2 (en) * 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
CN105229010A (zh) * 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
US20160022701A1 (en) * 2013-03-13 2016-01-28 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2699445T3 (es) 2013-03-13 2019-02-11 Sage Therapeutics Inc Esteroides neuroactivos y métodos de utilización de los mismos
US10259840B2 (en) * 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10238664B2 (en) * 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
CA2991311A1 (en) * 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof

Also Published As

Publication number Publication date
CN112121171A (zh) 2020-12-25
PE20170907A1 (es) 2017-07-12
EP3204011A4 (en) 2018-06-20
WO2016057713A1 (en) 2016-04-14
US20170304321A1 (en) 2017-10-26
CA2963938A1 (en) 2016-04-14
US20230218638A1 (en) 2023-07-13
AU2021200721A1 (en) 2021-03-04
CA2963938C (en) 2023-10-24
KR20170065637A (ko) 2017-06-13
JP2022033285A (ja) 2022-02-28
JP2020196759A (ja) 2020-12-10
AU2015330906A1 (en) 2017-04-27
SG11201702799UA (en) 2017-05-30
JP2017530982A (ja) 2017-10-19
EP3204011A1 (en) 2017-08-16
BR112017007053A2 (pt) 2018-06-19
IL251505A0 (en) 2017-05-29
MX2017004684A (es) 2017-06-30
NZ730862A (en) 2024-01-26
ZA201702545B (en) 2019-06-26
RU2017115849A3 (es) 2019-05-15
AU2021200721B2 (en) 2023-06-01
CN107405352A (zh) 2017-11-28
RU2764702C2 (ru) 2022-01-19
PH12017500639A1 (en) 2017-09-25
RU2017115849A (ru) 2018-11-13
IL292465A (en) 2022-06-01
IL251505B (en) 2022-05-01
SG10202011773UA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
MX2021011939A (es) Compuestos neuroactivos y metodos de uso de los mismos.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12017500692A1 (en) Antibody molecules to pd-l1 and uses thereof
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX367420B (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
GB2541571A (en) Pharmaceutical compositions
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
NZ737399A (en) Ccr2 modulators
WO2016100619A3 (en) Treatment and diagnosis of cancer
PH12016501366A1 (en) Novel anti-baff antibodies
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
TW201713333A (en) Methods of treating a neurodegenerative disease
MX354818B (es) Moduladores del receptor x del higado.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
NZ715582A (en) Lectin-like oxidized ldl receptor 1 antibodies and methods of use
EA201491894A1 (ru) Способы лечения непереносимости лактозы
IN2014KN02993A (es)
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016015298A (es) Inhibidores de nampt y metodos.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders